DUBLIN, Mar. 30, 2015 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/kh9jlj/liquid_biopsy_an) has announced the addition of the "Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management" report to their offering.
Cancer diagnostics based on measuring biomarkers in tissue samples has already in the past decade provided revolutionary advances in diagnosis, prognosis, and therapy selection. A major drawback of the tissue-based approach centers on the need for invasive surgical procedures in sample collection, which in a great many instances preclude following the progression or regression of disease during therapy.
In recent years, an impressive number of cancer biomarker researchers have turned their attention to the analysis of markers present in biological fluids, which can be collected with minimal invasiveness and permit following the disease over time. This highly dynamic field has come to be called liquid biopsy. In the past few years a significant and growing number of startups and several major companies have taken up the challenge of commercializing and offering liquid biopsy products and services to the market
These procedures, for the most part, query blood samples for information to be gleaned from circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) fragments, and extracellular vesicles (EVs). CTCs have the longest history as subjects for liquid biopsy. Indeed, one decade-old commercial product has already garnered FDA approval for in vitro diagnostic use. Circulating tumor DNA, a more recent entry on the liquid biopsy scene, is fast becoming an alternative or adjunct to CTC assays. EVs are the newest and least developed of the three liquid biopsy sample sources, and while highly promising, their ultimate value has yet to be fully established.
The report delves deeply into recent progress and emerging trends in this highly dynamic area of research and commerce.
Key Topics Covered:
- Executive Summary
- Chapter Introduction
- Chapter Background and History
- Chapter Liquid Biopsy Research
- Chapter Commercial Aspects of Liquid Biopsy
- Market Dynamics
- Liquid Biopsy Trends
- Interview Transcripts
- Agena Bioscience
- Angle plc
- Boreal Genomics
- Chronix Biomedical
- Circulating tumor DNA (ctDNA)
- Clearbridge BioMedics
- Cytolumina Technologies Corp.
- Diagnologix LLC
- Epic Sciences
- Exosome Diagnostics
- Exosome Sciences Inc.
- Extracellular vesicles (EVs)
- Fluxion Biosciences
- Genomic Health
- Molecular MD
- Myriad Genetics
- Personal Genome Diagnostics
- Rarecells SAS
- SRI International
- Silicon Biosystems
- Sysmex Inostics
For more information visit http://www.researchandmarkets.com/research/kh9jlj/liquid_biopsy_an
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets